SCR130

Overview

SCR130 is a SCR7-based DNA nonhomologous end-joining (NHEJ) inhibitor. SCR130 inhibits the end-joining of DNA in a Ligase IV-dependent manner. SCR130 is specific to Ligase IV, and shows minimal or no effect on Ligase III and Ligase I mediated joining. SCR130 induces cell apoptosis and has anticancer activity.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Digestive System Inflammation | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-139297
• CAS No.: 2377858-38-1
• Molecular Formula: C19H13Cl2N3O2S
• Molecular Weight: 418.30
• Purity: 98.23%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.98 mM); Clear solution
• Availability: In-stock

Source

Original product source